Apr 24 |
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncolo...
|
Apr 23 |
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
|
Apr 16 |
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
|
Apr 16 |
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
|
Apr 12 |
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
|
Apr 12 |
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
|
Apr 8 |
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
|
Apr 6 |
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
|
Apr 3 |
FibroGen falls after early-stage data for prostate cancer drug
|
Apr 3 |
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
|